- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06268769
Rapporto C:D del tacrolimus misurato in pazienti sottoposti a trapianto renale trattati con farmaci a rilascio prolungato una volta al giorno (TaC:Drop)
Studio di superiorità multicentrico, in aperto, randomizzato, a due bracci, a gruppi paralleli, per valutare la biodisponibilità e la praticabilità di due formulazioni di Tacrolimus monogiornaliero, Envarsus® rispetto ad Advagraf™, somministrate in pazienti sottoposti a trapianto di rene
The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.
The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.
Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.
Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Aachen, Germania, 52074
- University Hospital Aachen, Department of General, Visceral and Transplant Surgery
-
Berlin, Germania, 10117
- Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
-
Bochum, Germania, 44892
- Knappschaft Clinic, University Hospital Bochum, Department of Surgery
-
Dresden, Germania, 01307
- University Hospital Dresden, Division of Nephrology
-
Hamburg, Germania, 20251
- University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
-
Hanover, Germania, 30625
- Hannover Medical School, Department of General, Visceral and Transplant Surgery
-
Jena, Germania, 07747
- University Hospital Jena, Internal Medicine III, Nephrology
-
Mainz, Germania, 55131
- University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
-
Mannheim, Germania, 68167
- University Hospital Mannheim, Medical Clinic V
-
Munich, Germania, 81377
- LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
-
Münster, Germania, 48149
- University Hospital Münster, Medical Clinic D
-
Regensburg, Germania, 93053
- University Hospital Regensburg, Department of Nephrology
-
Würzburg, Germania, 97080
- University Hospital Würzburg, Medical Clinic I, Department of Nephrology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed and dated written informed consent
- Adult (≥18 years old) male or female
- Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
- ABO blood type compatible with the donor kidney
- Able to swallow an oral formulation of tacrolimus in tablet or capsule form
Exclusion Criteria:
- Multi-organ transplantation
- Any previous solid organ transplantation (other than a first kidney allograft)
- For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
- Patient and/or donor is positive for active HCV, HBV or HIV infection
- History of any malignancy that could not be curatively treated
- Ongoing abuse of drugs or alcohol
- Signs of advanced liver disease or any signs of liver decompensation
- Ongoing uncontrolled systemic infection
- Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
- Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
- Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
- Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
- Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
- Inability to freely give informed consent (e.g. individuals under legal guardianship)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Envarsus
Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Altri nomi:
|
|
Comparatore attivo: Advagraf
Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Lasso di tempo: 12 weeks after kidney transplantation
|
To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory. |
12 weeks after kidney transplantation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proporzione di pazienti con livelli minimi inferiori, compresi o superiori all'intervallo target
Lasso di tempo: 4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
|
|
Livello minimo medio di tacrolimus e variabilità interpaziente (intervallo) dei livelli minimi di tacrolimus
Lasso di tempo: 4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
|
|
Dose giornaliera media di tacrolimus e variabilità interpaziente (intervallo) della dose giornaliera di tacrolimus
Lasso di tempo: 4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
4 giorni, 14 giorni, 28 giorni e 12 settimane dopo il trapianto di rene
|
|
|
Variabilità intra-paziente del rapporto C/D e della dose giornaliera
Lasso di tempo: Misurato nei punti temporali: giorno 4, giorno 14, giorno 28 e settimana 12
|
Misurato nei punti temporali: giorno 4, giorno 14, giorno 28 e settimana 12
|
|
|
Tasso di incidenza delle biopsie per causa
Lasso di tempo: 12 settimane dopo il trapianto di rene
|
12 settimane dopo il trapianto di rene
|
|
|
Tasso di incidenza degli episodi di rigetto acuto che richiedono trattamento
Lasso di tempo: 12 settimane dopo il trapianto di rene
|
12 settimane dopo il trapianto di rene
|
|
|
Tasso di incidenza di episodi di rigetto acuto resistenti agli steroidi confermati dalla biopsia
Lasso di tempo: 12 settimane e 1 anno dopo il trapianto di rene
|
12 settimane e 1 anno dopo il trapianto di rene
|
|
|
Incidenza dell'infezione da CMV e BKV (compresa la manifestazione d'organo, se rilevante)
Lasso di tempo: 12 settimane e 1 anno dopo il trapianto di rene
|
12 settimane e 1 anno dopo il trapianto di rene
|
|
|
Incidenza, tipo, gravità e gravità delle reazioni avverse (AR)
Lasso di tempo: 12 settimane e 3 anni dopo il trapianto di rene
|
12 settimane e 3 anni dopo il trapianto di rene
|
|
|
Pressione sanguigna
Lasso di tempo: 12 settimane e 1, 2, 3 anni dopo il trapianto di rene
|
12 settimane e 1, 2, 3 anni dopo il trapianto di rene
|
|
|
Incidenza di disturbi gastrointestinali che richiedono indagini diagnostiche
Lasso di tempo: 12 settimane e 3 anni dopo il trapianto di rene
|
12 settimane e 3 anni dopo il trapianto di rene
|
|
|
Recidiva di malattia renale primaria
Lasso di tempo: 12 settimane e 3 anni dopo il trapianto di rene
|
12 settimane e 3 anni dopo il trapianto di rene
|
|
|
Incidenza dei DSA de novo
Lasso di tempo: Rilevato entro il primo anno dopo il trapianto di rene
|
Rilevato entro il primo anno dopo il trapianto di rene
|
|
|
Dosi e durata del trattamento con glucocorticosteroidi
Lasso di tempo: 12 settimane e 1, 2, 3 anni dopo il trapianto di rene
|
12 settimane e 1, 2, 3 anni dopo il trapianto di rene
|
|
|
Incidenza e tempo per studiare l’interruzione del trattamento
Lasso di tempo: 3 anni dopo il trapianto di rene
|
3 anni dopo il trapianto di rene
|
|
|
Incidenza, tempo e motivo del ritiro del paziente dallo studio
Lasso di tempo: 3 anni dopo il trapianto di rene
|
3 anni dopo il trapianto di rene
|
|
|
Time to reach the first trough level in target range
Lasso di tempo: Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading |
Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
|
Tacrolimus concentration/dose (C/D) ratio
Lasso di tempo: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site. |
4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
|
Treatment failure rate
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause) |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Time to treatment failure after transplantation
Lasso di tempo: Measured until 3 years after kidney transplantation
|
Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause) |
Measured until 3 years after kidney transplantation
|
|
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition. |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of graft failure
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Mortality rate
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Mortality rate measures death from any cause |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Graft function measured by eGFR (estimated glomerular filtration rate)
Lasso di tempo: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
eGFR calculated according to the CKD-EPI formula |
4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of delayed graft function
Lasso di tempo: Measurable within the first 2 weeks after kidney transplantation
|
Delayed graft function is defined as the need for more than one episode of dialysis after transplantation |
Measurable within the first 2 weeks after kidney transplantation
|
|
Incidence rate of primary non-function of the renal allograft
Lasso di tempo: Measurable within the first 12 weeks after kidney transplantation
|
Primary non-function is defined as the necessity for ongoing chronic dialysis |
Measurable within the first 12 weeks after kidney transplantation
|
|
Incidence of hepatotoxicity
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence of de novo tremor
Lasso di tempo: 12 weeks and 3 years after kidney transplantation
|
Incidence and severity of tremor based on medical assessment by the investigator |
12 weeks and 3 years after kidney transplantation
|
|
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Lasso di tempo: 12 weeks and 3 years after kidney transplantation
|
The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients. |
12 weeks and 3 years after kidney transplantation
|
|
Dose of mycophenolate
Lasso di tempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Including both mycophenolate mofetil and mycophenolic acid |
12 weeks and 1, 2, 3 years after kidney transplantation
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Bernhard Banas, MD, University Hospital Regensburg
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TaC:Drop
- 2023-503531-18-00 (Altro identificatore: EUCT Number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .